Based on the key indicators related to Arcus Biosciences' liquidity, profitability, solvency, and operating efficiency, Arcus Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Arcus Biosciences' Property Plant Equipment is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 473.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 99.4 M in 2024. Key indicators impacting Arcus Biosciences' financial strength include:
The essential information of the day-to-day investment outlook for Arcus Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Arcus Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Arcus Biosciences.
Net Income
(291.65 Million)
Arcus
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Account Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Change To Inventory
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Long Term Investments
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Common Stock
Property Plant Equipment
Current Deferred Revenue
Common Stock Total Equity
Deferred Long Term Liab
Net Invested Capital
Net Working Capital
Short Term Debt
Retained Earnings Total Equity
Capital Stock
Short Long Term Debt Total
Capital Lease Obligations
Inventory
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Reconciled Depreciation
Non Operating Income Net Other
Tax Provision
Probability Of Bankruptcy
Understanding current and past Arcus Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arcus Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Arcus Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Arcus Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcus Biosciences. Check Arcus Biosciences' Beneish M Score to see the likelihood of Arcus Biosciences' management manipulating its earnings.
Arcus Biosciences Stock Summary
Arcus Biosciences competes with Cullinan Oncology, Annexon, Structure Therapeutics, Relay Therapeutics, and Day One. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Arcus Biosciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Arcus Biosciences's current stock value. Our valuation model uses many indicators to compare Arcus Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcus Biosciences competition to find correlations between indicators driving Arcus Biosciences's intrinsic value. More Info.
Arcus Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Arcus Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcus Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Arcus Biosciences Systematic Risk
Arcus Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arcus Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Arcus Biosciences correlated with the market. If Beta is less than 0 Arcus Biosciences generally moves in the opposite direction as compared to the market. If Arcus Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arcus Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arcus Biosciences is generally in the same direction as the market. If Beta > 1 Arcus Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Arcus Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcus Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arcus Biosciences growth as a starting point in their analysis.
Arcus Biosciences November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arcus Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arcus Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arcus Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Arcus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcus Biosciences's daily price indicators and compare them against related drivers.
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.